Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 56 of the 57 references it cites were found in a registry or an index.

Physical Fitness with Exercise and GLP-1 Receptor Agonist Treatment Alone or Combined After Diet-Induced Weight Loss: A Secondary Analysis of a Randomized Controlled Trial in Adults with Obesity

Open access

Abstract

Background: Obesity is associated with impaired physical fitness, including physical functional performance and cardiorespiratory fitness, which affect health-related quality of life and mortality. Objective: We aimed to investigate the efficacy of a moderate-to-vigorous intensity exercise program and glucagon-like peptide-1 receptor agonist treatment alone or in combination during weight maintenance for physical fitness. Methods: This is secondary analysis of a randomized controlled trial involving 193 adults with obesity (age 18–65 years, body mass index 32–43 kg/m 2 ) without diabetes mellitus who completed an 8-week low-calorie diet and were subsequently randomized (1:1:1:1 ratio) to: exercise plus placebo; glucagon-like peptide-1 receptor agonist liraglutide 3 mg once-daily plus usual activity; exercise plus liraglutide combined; or placebo plus usual activity. The exercise program was a combination of group sessions (interval-based indoor cycling followed by circuit training) and individual sessions of moderate-to-vigorous intensity, designed to meet the World Health Organization recommendations on physical activity for health. Exercise adherence was measured with sports watches and heart rate monitors. Key secondary endpoints related to physical fitness were changes from randomization to the end of treatment (weeks 0–52) in: (1) physical functional performance (time to ascend and descend an 11-step stairway twice); (2) cardiorespiratory fitness (peak oxygen consumption normalized to fat-free mass); and (3) muscle strength (isometric knee extensor peak torque). Results: Participants randomized to exercise performed a median 2.65 session/week (116 min/week at 79% of maximum heart rate) with no significant difference between those who received placebo or liraglutide. Compared with liraglutide alone, the combined treatment decreased time to complete a stair climb test by 1.2 s [95% confidence interval 0.6–1.9] (corresponding to 8.6%) and improved peak oxygen consumption by 3.0 mL/min/kg fat-free mass [95% confidence interval 0.5–5.5]. Exercise alone led to similar benefits, whereas liraglutide alone did not improve physical fitness. Compared with placebo (− 7.8%), relative muscle strength (strength normalized to body weight) was higher with exercise (− 0.4%), liraglutide (+ 1.0%), and the combined treatment (+ 3.3%) because of lower weight and preserved absolute strength. Conclusions: Structured exercise combined with glucagon-like peptide-1-based obesity pharmacotherapy led to clinically meaningful improvements in physical functional performance and cardiorespiratory fitness, in contrast to pharmacotherapy alone. Clinical Trial Registration: EudraCT number, 2015-005585-32; ClinicalTrials.gov number, NCT04122716.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40279-025-02386-0

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Exercise duration and body composition. a Box plots of exercise duration after the program was fully implemented (weeks 7–52 after randomization). Data are shown for participants who attended week 52 (n = 40 for exercise alone and n = 44 for combined exercise and liraglutide). Intensities were defined as the percentage of maximum heart rate derived from an incremental maximal cycle test: light-intensity exercise, 50–63%; moderate-intensity exercise, 64–76%; and vigorous-intensity exercise, ≥ 77%. In the box plots, the lines inside the boxes indicate medians; the boxes are interquartile ranges (from the first quartile to the third quartile); the crosses are observed means; and the whiskers are the smallest and largest values within 1.5 × the interquartile range. Dots indicate individual participant values. b Observed mean ± standard error changes relative to randomization in body weight during the low-calorie diet (week − 8 to 0) for all participants and from randomization (week 0) to week 52 for the four randomized groups. c Least-squares mean ± standard error appendicular fat-free mass over time. d Least-squares mean ± standard error appendicular fat-free mass relative to body weight over time. Data in b–d are from the full analysis set (all randomized irrespective of completion and treatment discontinuation), and data in c and d were derived from constrained linear mixed models (see Sect. 2.8 for details)
Fig. 1 Exercise duration and body composition. a Box plots of exercise duration after the program was fully implemented (weeks 7–52 after randomization). Data are shown for participants who attended week 52 (n = 40 for exercise alone and n = 44 for combined exercise and liraglutide). Intensities were defined as the percentage of maximum heart rate derived from an incremental maximal cycle test: light-intensity exercise, 50–63%; moderate-intensity exercise, 64–76%; and vigorous-intensity exercise, ≥ 77%. In the box plots, the lines inside the boxes indicate medians; the boxes are interquartile ranges (from the first quartile to the third quartile); the crosses are observed means; and the whiskers are the smallest and largest values within 1.5 × the interquartile range. Dots indicate individual participant values. b Observed mean ± standard error changes relative to randomization in body weight during the low-calorie diet (week − 8 to 0) for all participants and from randomization (week 0) to week 52 for the four randomized groups. c Least-squares mean ± standard error appendicular fat-free mass over time. d Least-squares mean ± standard error appendicular fat-free mass relative to body weight over time. Data in b–d are from the full analysis set (all randomized irrespective of completion and treatment discontinuation), and data in c and d were derived from constrained linear mixed models (see Sect. 2.8 for details)CC BY · PubMed Central
Fig. 2 Physical functional performance. a Physical functional performance over time measured as the time to complete a stair climb test. Values are least square mean ± standard error. b Least square mean ± 95% confidence interval changes in the stair climb test in response to the low-calorie diet for all participants (weeks − 8 to 0) and from randomization (week 0) to week 52 for the four randomized treatment groups. P-values are provided for statistically significant between-group differences (P < 0.05, and the Benjamini–Hochberg procedure to control the false discovery rate). All data were derived from constrained linear mixed models (see Sect. 2.8 for details), which included all randomized participants who received at least one randomized treatment dose, irrespective of completion and treatment adherence
Fig. 2 Physical functional performance. a Physical functional performance over time measured as the time to complete a stair climb test. Values are least square mean ± standard error. b Least square mean ± 95% confidence interval changes in the stair climb test in response to the low-calorie diet for all participants (weeks − 8 to 0) and from randomization (week 0) to week 52 for the four randomized treatment groups. P-values are provided for statistically significant between-group differences (P < 0.05, and the Benjamini–Hochberg procedure to control the false discovery rate). All data were derived from constrained linear mixed models (see Sect. 2.8 for details), which included all randomized participants who received at least one randomized treatment dose, irrespective of completion and treatment adherenceCC BY · PubMed Central
Fig. 3 Cardiorespiratory fitness. a Cardiorespiratory fitness over time expressed as least square mean ± standard error peak oxygen consumption (V̇O2peak) relative to fat-free mass. b Least square mean ± 95% confidence interval changes in V̇O 2peak relative to fat-free mass in response to the low-calorie diet for all participants (week − 8 to 0) and from randomization (week 0) to week 52 for the four randomized treatment groups. P-values are provided for statistically significant between-group differences (P < 0.05, and the Benjamini–Hochberg procedure to control the false discovery rate). c Least square mean ± standard error V̇O2peak relative to body weight over time. d Least square mean ± standard error absolute V̇O2peak over time. e Exercise tolerance expressed as Least square mean ± standard error peak power output reached during the incremental cycle test over time. All data were derived from constrained linear mixed models (see Sect. 2.8 for details), which included all randomized participants who received at least one randomized treatment dose, irrespective of completion and treatment adherence. min minutes
Fig. 3 Cardiorespiratory fitness. a Cardiorespiratory fitness over time expressed as least square mean ± standard error peak oxygen consumption (V̇O2peak) relative to fat-free mass. b Least square mean ± 95% confidence interval changes in V̇O 2peak relative to fat-free mass in response to the low-calorie diet for all participants (week − 8 to 0) and from randomization (week 0) to week 52 for the four randomized treatment groups. P-values are provided for statistically significant between-group differences (P < 0.05, and the Benjamini–Hochberg procedure to control the false discovery rate). c Least square mean ± standard error V̇O2peak relative to body weight over time. d Least square mean ± standard error absolute V̇O2peak over time. e Exercise tolerance expressed as Least square mean ± standard error peak power output reached during the incremental cycle test over time. All data were derived from constrained linear mixed models (see Sect. 2.8 for details), which included all randomized participants who received at least one randomized treatment dose, irrespective of completion and treatment adherence. min minutesCC BY · PubMed Central
Fig. 4 Muscle strength. a Absolute maximal muscle strength over time expressed as least square mean ± standard error knee extensor peak torque. b Least square mean ± 95% confidence interval changes in knee extensor peak torque in response to the low-calorie diet for all participants (week − 8 to 0) and from randomization (week 0) to week 52 for the four randomized treatment groups. No between-group comparisons were statistically significant. c Least square mean ± standard error knee extensor peak torque relative to body weight over time. d Muscle quality expressed as least square mean ± standard error knee extensor peak torque relative to leg fat-free mass over time. All data were derived from constrained linear mixed models (see Sect. 2.8 for details), which included all randomized participants who received at least one randomized treatment dose, irrespective of completion and treatment adherence. Nm newton meter
Fig. 4 Muscle strength. a Absolute maximal muscle strength over time expressed as least square mean ± standard error knee extensor peak torque. b Least square mean ± 95% confidence interval changes in knee extensor peak torque in response to the low-calorie diet for all participants (week − 8 to 0) and from randomization (week 0) to week 52 for the four randomized treatment groups. No between-group comparisons were statistically significant. c Least square mean ± standard error knee extensor peak torque relative to body weight over time. d Muscle quality expressed as least square mean ± standard error knee extensor peak torque relative to leg fat-free mass over time. All data were derived from constrained linear mixed models (see Sect. 2.8 for details), which included all randomized participants who received at least one randomized treatment dose, irrespective of completion and treatment adherence. Nm newton meterCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 57 references

Cited by

See all 9

Metadata

Authors
Jensen, S. B. K., Fiorenza, M., Juhl, C. R., Sandsdal, R. M., Jensen, E., Seier, S. S., Janus, C., Jørgensen, J. R., Blond, M. B., Holst, J. J., Stallknecht, B. M., Madsbad, S., Bandholm, T., & Torekov, S. S.
Affiliations
  • University of Copenhagen (DK)
  • Steno Diabetes Center Copenhagen (DK)
Corresponding author
  • Jensen, Simon Birk Kjær
  • Torekov, Signe Sørensen
Venue
Sports Medicine
Published
2026-01-24
Volume
56
Issue
7
Pages
1785-1800
ISSN
  • 0112-1642 (ISSN-L)
  • 1179-2035
OpenAlex
W7125578635
Cited by
9
References
57
Citations by year
2026: 9
FWCI
41.14
Type
journal article
Language
en
Open access
Licence
Locations
  • Sports Medicine (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
Funders
  • Novo Nordisk Fonden (NNF16OC0019968, NNF15CC0018486)
  • Helsefonden
  • Novo Nordisk Foundation Center for Basic Metabolic Research
  • Danish Diabetes and Endocrine Academy
  • Danish Cardiovascular Academy
  • Det Sundhedsvidenskabelige Fakultet, Københavns Universitet
  • Copenhagen University
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Physical Activity and Health
  • Health Sciences › Medicine › Physiology (medical) › Cardiovascular and exercise physiology
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
obesity, physical fitness, physical activity, liraglutide, GLP-1 receptor agonists, weight maintenance, hypocaloric diet, cardiorespiratory fitness, peak oxygen uptake, physical functional performance, muscle strength, quadriceps strength, weight loss, exercise adherence, circuit training, health-related quality of life
MeSH terms
Liraglutide, Cardiorespiratory Fitness, Glucagon-Like Peptide-1 Receptor Agonists, Adolescent, Adult, Aged, Combined Modality Therapy, Diet, Reducing, Exercise Therapy, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Obesity, Physical Fitness, Weight Loss, Caloric Restriction, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Physical Fitness with Exercise and GLP-1 Receptor Agonist Treatment Alone or Combined After Diet-Induced Weight Loss: A Secondary Analysis of a Randomized Controlled Trial in Adults with Obesity. https://app.cochat.ai/papers/10.1007/s40279-025-02386-0
The paper
Jensen, S. B. K., Fiorenza, M., Juhl, C. R., Sandsdal, R. M., Jensen, E., Seier, S. S., Janus, C., Jørgensen, J. R., Blond, M. B., Holst, J. J., Stallknecht, B. M., Madsbad, S., Bandholm, T., & Torekov, S. S. (2026). Physical Fitness with Exercise and GLP-1 Receptor Agonist Treatment Alone or Combined After Diet-Induced Weight Loss: A Secondary Analysis of a Randomized Controlled Trial in Adults with Obesity. Sports Medicine. https://doi.org/10.1007/s40279-025-02386-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.